Treatment of chronic hepatitis C virus infection at the beginning of a new era

Czech version

Authors: P. Urbánek
Authors‘ workplace: Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MU Dr. Miroslav Zavoral, Ph. D.
Published in: Vnitř Lék 2013; 59(7): 612-617
Category:

Overview

After 2010 the therapy of chronic HCV infection entered a completely new era –⁠ the era that is marked with the gradual introduction of the so ‑⁠ called directly acting antivirals into treatment schemes of this serious disease. The term directly acting antivirals (DAA) covers low ‑⁠ molecular substances that inhibit viral non‑structural proteins –⁠ enzymes involved in the HCV replication cycle. At present, the first 2 representatives of DAA, Boceprevir and Telaprevir, have been approved for chronic HCV infection indication. The synoptic article pays the greatest attention to these 2 representatives, along with mentioning some other substances that are under later phases of clinical development and are likely to be approved in the near future.

Key words:
chronic hepatitis C –⁠ pegylated interferon –⁠ ribavirin –⁠ boceprevir –⁠ telaprevir

Sources

1. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment‑induced viral clearance. Nature 2009; 461 : 399 –⁠ 401.

2. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 : 1207 –⁠ 1217.

3. Zeuzem S, Andreone P, Pol S. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 : 2417 –⁠ 2428.

4. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 : 1195 –⁠ 1206.

5. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 : 2405 –⁠ 2416.

6. Sherman KE, Flamm SL, Afdhal NH et al. Response ‑⁠ guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365 : 1014 –⁠ 1024.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 : 245 –⁠ 264.

8. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54 : 1433 –⁠ 1444.

9. Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2012; 26 : 214 –⁠ 229.

10. Lalezari LP, Nelson DR, Hyland RH et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment ‑⁠ naive patients with HCV infection: the QUANTUM study. Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24. –⁠ 28. 4. 2013. Abstract 845.

11. Sulkowski MS, Gardiner DF, Rodroguez ‑⁠ Torres M et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1 –⁠ infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24. –⁠ 28. 4. 2013. Abstract 1417.

12. Kowdley KV, Lawitz E, Poordad F et al. Safety and efficacy of interferon‑free regimens of ABT ‑⁠ 450/ R, ABT ‑⁠ 267, ABT ‑⁠ 333 ± ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24. –⁠ 28. 4. 2013. Abstract 3.

13. Kowdley KV, Lawitz E, Poordad F et al. A 12‑week interferon‑free treatment regimen with ABT ‑⁠ 450/ r, ABT ‑⁠ 267, ABT ‑⁠ 333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment ‑⁠ naive patients and 93% in prior null responders with HCV genotype 1 infection. Abstracts 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston 9. –⁠ 13. 11. 2012. Abstract LB ‑⁠ 1.